Effects of Estrogenic Oral Contraceptives on the Lipoprotein B Particle System Defined by Apolipoproteins E and C-III Content
Overview
Affiliations
Apolipoproteins E and C-III are modulators of lipoprotein metabolism that could affect development of atherosclerosis. The prevalence in plasma of apoB-containing particles (LpB) that contain either apoE or apoC-III, both or neither, and the effect of estrogen on these lipoproteins are unknown. The LpB particle system, defined by the presence or absence of apoE or C-III, was studied in 13 normolipidemic women, 7 nonusers and 6 users of oral contraceptives. Fasting plasma was separated by anti-apoE and C-III affinity chromatography and ultracentrifugation into four types of VLDL, IDL, and LDL particles: with apoE but not apoC-III (E+C-), apoC-III but not apoE (E-C+), both (E+C+) or neither (E-C-). The predominant VLDL particles were E-C- (42% in nonusers, 56% in users) and E+C+ (39% in nonusers, 24% in users), suggesting that apoE and apoC-III mainly exist together in VLDL. In IDL, E-C- was the major fraction (74% nonusers, 81% users), and in LDL, it was 99% in both groups. The triglycerides in VLDL and IDL were mainly contained in C+ particles (79% and 66% of the total VLDL and IDL triglycerides, respectively). Within VLDL, IDL, and LDL, E-C- particles had the smallest size and E+C+ or E-C+ the largest. Users had higher concentrations of VLDL E-C- (280%) and IDL E-C- (90%) particles than nonusers. They also had higher free cholesterol and cholesteryl ester concentrations associated with these fractions and with VLDL E-C+. The triglyceride contents of VLDL E-C- particles were lower in users of oral contraceptives than in nonusers. This study demonstrates that the elevated VLDL TG concentrations in users of estrogen-dominant oral contraceptives is mainly caused by an increased concentration of small VLDL particles that have reduced TG content, and that do not have apoE and C-III. These particles may have lower atherogenicity than particles enriched with apoE and C-III.-Khoo, C., H. Campos, H. Judge, and F. M. Sacks. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content.
Li J, Sun H, Wang Y, Liu J, Wang G Lipids Health Dis. 2023; 22(1):29.
PMID: 36855114 PMC: 9972754. DOI: 10.1186/s12944-023-01797-0.
Tsai P, Chen L, Tseng K, Chen F, Shen M Biomedicines. 2022; 10(4).
PMID: 35453604 PMC: 9028166. DOI: 10.3390/biomedicines10040854.
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle.
Valladolid-Acebes I, Berggren P, Juntti-Berggren L Int J Mol Sci. 2021; 22(2).
PMID: 33477763 PMC: 7832341. DOI: 10.3390/ijms22020932.
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Boren J, Packard C, Taskinen M Front Endocrinol (Lausanne). 2020; 11:474.
PMID: 32849270 PMC: 7399058. DOI: 10.3389/fendo.2020.00474.
Sex hormones affect endothelial lipase-mediated lipid metabolism and atherosclerosis.
Wang C, Niimi M, Kitajima S, Matsuhisa F, Yan H, Dong S Lipids Health Dis. 2019; 18(1):226.
PMID: 31870448 PMC: 6929444. DOI: 10.1186/s12944-019-1175-4.